Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients

Vincenzo Trovato; Ashlee Asada; Lynn Fussner; Casey Curtis; Rami Kahwash

doi:10.1016/j.jaccas.2024.102267

Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients

JACC Case Rep. 2024 Feb 27;29(7):102267. doi: 10.1016/j.jaccas.2024.102267. eCollection 2024 Apr 3.

Authors

Vincenzo Trovato¹, Ashlee Asada², Lynn Fussner³, Casey Curtis⁴, Rami Kahwash¹

Affiliations

¹ Division of Cardiovascular Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
² Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
³ Division of Pulmonary, Critical Care, and Sleep Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁴ Division of Allergy and Immunology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Abstract

Eosinophilic myocarditis (EM) is a rare disease associated with significant morbidity and mortality. This case series follows the clinical courses of 3 patients with EM. The use of mepolizumab, an anti-interleukin-5 monoclonal antibody, as an adjunctive treatment was associated with stabilization of cardiac function and improved long-term outcomes.

Keywords: eosinophilic myocarditis; interleukin-5; myocarditis; reduced ejection fraction; steroid-sparing.

Publication types

Case Reports